// App-Quantinova.ai

: Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study

Researchers

Presenter

  • Howland E. Crosswell

Principal Investigators

  • Ann S. LaCasce

  • Nancy L. Bartlett

  • David J. Straus

  • Kerry J Savage

  • Keenan Fenton

  • Gerald Engley

  • Hina Jolin

  • Rachael Liu

  • Pier Luigi Zinzani

  • Graham P. Collins

  • Andrew P. Grigg

Medical Centers

  • Bon Secours Hematology Oncology, Bon Secours St. Francis Health System, Greenville, SC

  • Dana-Farber Cancer Institute, Harvard Cancer Center, Boston, MA

  • Alvin J Siteman Cancer Center at Washington University School of Medicine, St. Louis, MO

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Seattle Genetics, Bothell, WA

  • Takeda Oncology, Cambridge, MA.

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Department of Clinical Haematology, Austin Hospital, Melbourne, Australia

Locations

  • United States

  • Canada

  • Italy

  • United Kingdom

  • Australia

Companies

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved